JINGXIN(SZ:002020) Ping An Securities·2025-09-04 00:44Investment Rating - The report maintains a "Recommended" investment rating for Jingxin Pharmaceutical (002020.SZ) [1][8][10] Core Views - The company is expected to see continued growth in its innovative pipeline, particularly with the ongoing expansion of its first-class innovative drug, Didasinib [7][8] - The company reported a revenue of 2.017 billion yuan for H1 2025, a year-on-year decrease of 6.20%, while the net profit attributable to shareholders was 388 million yuan, down 3.54% year-on-year [4][7] - The report anticipates that the company will achieve revenues of 4.724 billion yuan, 5.357 billion yuan, and 6.092 billion yuan for the years 2025, 2026, and 2027, respectively, with year-on-year growth rates of 13.6%, 13.4%, and 13.7% [6][8] Financial Performance - In H1 2025, the company's revenue from finished drugs was 1.175 billion yuan, down 9.68% year-on-year, while revenue from medical devices increased by 12.01% to 349 million yuan [7] - The gross margin for H1 2025 was 49.57%, a decrease of 2.00 percentage points year-on-year, while the net margin increased by 0.57 percentage points to 19.45% [7] - The company expects to maintain its profit forecasts, projecting net profits of 829 million yuan, 947 million yuan, and 1.102 billion yuan for 2025, 2026, and 2027, respectively, with year-on-year growth rates of 16.4%, 14.3%, and 16.4% [8] Innovative Pipeline - The innovative drug Didasinib has seen significant growth, generating 55 million yuan in revenue in H1 2025, with over 1,500 hospitals now covered [7][8] - The company has a rich pipeline of drugs under development, including a first-class innovative drug for schizophrenia that has completed Phase II clinical trials and a new drug for cardiovascular diseases that is progressing through Phase I trials [7][8]